Health ministry not to use Itolizumab in clinical protocols for Covid-19

The permission to market the drug was granted for the treatment of cytokine release syndrome in moderate' to severe' Acute Respiratory Distress Syndrome patients due to Covid-19


Biocon, has been manufacturing and marketing Itolizumab under brand name ALZUMAb

Press Trust of India New Delhi
The National Task Force on Covid-19 has decided against including Itolizumab drug in clinical management protocols for treating the disease even though the DCGI has approved its "restricted emergency use" in infected patients, official sources said. 

Considering the unmet medical needs in Covid-19, Itolizumab, an already approved drug of Biocon, used for treating psoriasis - a skin condition - was approved for "restricted emergency use" in the treatment of coronavirus by the Drugs Controller General of India (DCGI) recently. 

Topics : Coronavirus

First Published: Jul 26 2020 | 5:47 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to